Director – has over 40 years of executive business experience in finance, auditing, governance & risk.
He is a retired Managing Partner – Assurance at Ernst and Young LLP, Chicago where he was responsible for more than 1,600 Assurance professionals in 10 offices across 12 states. Mr. Kaye currently is a member of the Board of Directors for Alliance Bernstein Holdings NYSE (AB), AXE Equitable Holdings NYSE (EQH) and CME Group.
GREG T. HERMANSON PH.D
has over 30 years of R&D management experience at Pierce Biotechnology and Thermo-Fisher Scientific Company.
Dr. Hermanson’s specialties include protein purification, protein chemistry, affinity separations, activation and coupling molecules to solid supports and surfaces, bioconjugation and modification, fluorescent probes and labeling, detection, and assay development. Dr. Hermanson also brings experience in negotiations, licensing and acquisition of technology, collaborative development, intellectual property management, strategic planning, and patent research and prosecution.
RICHARD BURGESS, PH.D.
is the James D. Watson Professor Emeritus in Oncology at the McArdle Laboratory for Cancer Research, University of Wisconsin-Madison.
He is considered a leading expert on protein purification and characterization, RNA polymerases and transcription machinery, regulation of gene expression, and use of monoclonal antibodies in protein biochemistry. He was the founder and director of the UW-Madison Biotechnology Center (1984-96) and is a leading figure in the Wisconsin biotechnology business community. He earned his B.S. in Chemistry from the California Institute of Technology and his Ph.D. in Biochemistry and Molecular Biology from Harvard University under James D Watson in 1969.
FRITZ SCHOMBURG PH.D.
is owner and President of Lytic Solutions LLC and a scientific advisor in protein
His work using proprietary vectors and “protease-free” expression and production systems to generate commercial quantities of robust, recombinant reagents, was instrumental in SBT’s previous work. He earned his B.S. in Biology and Chemistry from Drake University and completed his Ph.D. and postdoctoral work in Biochemistry at the University of Wisconsin-Madison.
DOUGLAS STAFFORD, PH.D.
is the Director of the Milwaukee Institute for Drug Discovery at the University of Wisconsin-Milwaukee.
Dr. Stafford has over 20 years of experience in biomedical product companies, with senior management responsibilities, in research and development, manufacturing operations, regulatory and clinical affairs, organizational development, patent licensing, and finance. Dr. Stafford is inventor on over a dozen biomedical patents. Dr. Stafford has participated in 5 early stage biotechnology companies having made the successful transition to operating companies with a full range of products.
is CEO and Founder of CTI, a multi-national research firm that has supported more than 100 drug and device approvals, and currently works on behalf of approximately 120 global pharmaceutical and biotechnology companies.
Mr. Schroeder has over 35 years of clinical, academic, and industry experience in global drug and device development programs. Prior to founding CTI, Mr. Schroeder held numerous faculty positions with the University of Cincinnati College of Medicine. He was also the founding Executive Vice President of Clinical Development at SangStat Medical Corporation, which went public in 1995.
JOSEPH BARRETT, R.PH., J.D.
is a recognized expert in the areas of technology identification, evaluation and development.
Mr. Barrett led the Business Development function for Baxter’s Cellular Therapies Group from 2003-2007 and the strategic angel investing group at Baxter from 2007-2013. Mr. Barrett has degrees in both pharmacy (R.Ph.) and law (J.D.).
ROBERT SELL J.D., PARTNER http://www.seyfarth.com/RobertSell, Seyfarth Shaw, LLP, Chicago Illinois,
Bob Sell is a Partner in the Chicago office of Seyfarth Shaw LLP, and is a member of the Firm’s Corporate Group. Mr. Sell is also a member and a leader of the Firm’s Technology Transactions sub-practice, and a member of the Corporate Group’s Mergers and Acquisitions sub-practice.